NCT02031666View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-56021927 capsule

Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.

DRUG

JNJ-56021927 tablet

Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.

Trial Locations (1)

Unknown

Tempe

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY